title: Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
abstract: It was estimated that small cell lung cancer (SCLC) accounts for about one Sixth of all lung cancer cases. Patients with SCLC are usually diagnosed in advanced stage of disease. Unfortunately at this stage, prognosis is very poor. Bevacizumab is a monoclonal antibody against VEGF, which inhibits the angiogenesis in malignant tumors. Although Bevacizumab has been approved for firstline use in advanced non-SCLC, the first report has been available for its use in SCLC. In this review, we summarized all available data on the use of Bev in SCLC patients. Finally, future directions are discussed.
authors.affiliation: Department of Molecular and Translational Medicine, University of Brescia, Viale Europa, 11 - 25123 Brescia, Italy. giandomenicoroviello@hotmail.it.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000068258:Bevacizumab / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab